Fig. 3.

Significant improvement in WHO Clinical Status Score in response to baricitinib plus dexamethasone and remdesivir therapy. Clinical illness severity was recorded at the time of admission and followed daily using the National Early Warning Score-2 (NEWS-2 score) [A] and 8-level ordinal scale of clinical status recommended by the World Health Organization Research and Development Blueprint Group (WHO Clinical Status Score) [B]. There was no statistically significant change in NEWS-2 scores. The start date of baricitinib, dexamethasone and remdesivir therapy for each patient was arbitrarily set as day 0. All observations were divided into early (up to day -3) and late periods (up to day + 9). Linear regressions were performed for each variable and a difference in slope tested between before treatment (day -3 to day 0) vs. after treatment (day + 1 to day + 9)